(Reuters Health) - Seniors who get new lenses implanted during cataract surgery may not only see better but also experience better sleep, suggests a new study of how light entering the eye regulates ...

Please provide your email address to receive an email when new articles are posted on . Omeros Corp. announced that the U.S. Food and Drug Administration has approved the use of phenylephrine and ...

Company to Host Conference Call Today at 9:00 a.m. EDT-- SEATTLE, March 13, 2012 /PRNewswire via COMTEX/ -- Omeros Corporation today reported positive data from its Phase 3 clinical trial evaluating ...

Omeros reported positive data from the second of its two pivotal Phase 3 clinical trials evaluating OMS302 in patients undergoing intraocular lens replacement surgery. This multicenter, double-blind, ...

SEATTLE, June 2, 2014--Omeros Corporation OMER +8.64% today announced that the U.S. Food and Drug Administration (FDA) has approved Omidria™ (phenylephrine and ketorolac injection) 1%/0.3% for use ...

It’s been a shining year so far for RxSight Inc., which makes an eye lens that can be customized after cataract surgery, which it claims is the only such product on the market. The Aliso Viejo-based ...

SEATTLE, Oct. 3, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that the last patient has been enrolled in the Company's second Phase 3 clinical trial evaluating OMS302 for use ...

Intraocular lenses (IOLs), implanted in the eye as treatment for cataracts or myopia, are a growing global market in an ageing population, one estimated to be worth more than $4.5 billion by 2022.

Omeros reported positive data from its Phase 3 clinical trial evaluating OMS302 in patients undergoing intraocular lens replacement surgery. OMS302 met its primary endpoint by demonstrating ...

The US Food and Drug Administration (FDA) has approved phenylephrine and ketorolac injection (Omidria, Omeros Corporation) 1%/3% for use during cataract surgery or intraocular lens replacement (ILR), ...